![]() | ![]() |
Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations: CLEAR-AD (U19 AG074879)
Mayo Clinic Florida and Indiana University School of Medicine are leading a $41 million NIH program over 5 years towards personalized medicine in Alzheimer’s disease (AD) and related disorders.
![](https://clear-ad.org/wp-content/uploads/2023/03/CLEAR-AD-Logo-2-842x1024.png)
CLEAR-AD Collaborating Organizations
![](https://clear-ad.org/wp-content/uploads/2023/03/Mayo_Clinic_logo.svg_.png)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture2.jpg)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture3.png)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture4.jpg)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture5.png)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture6.png)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture7.png)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture8.png)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture9.png)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture10.png)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture11.jpg)
![](https://clear-ad.org/wp-content/uploads/2023/03/Picture12.png)
![](https://clear-ad.org/wp-content/uploads/2024/05/adni3.png)
Clear-AD logo created with BioRender.org